Satellos Bioscience announced submission of a clinical research proposal to a Human Research Ethics Committee, or HREC, in Australia seeking regulatory authorization under their Therapeutic Goods Administration’s, or TGA’s, clinical trial notification, or CTN, scheme to conduct a first-in-human Phase 1 clinical trial of SAT-3247.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MSCLF: